Evidence map›Paper›PMID 33843043›Full record

Observational studyCardiology journal2021

Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19.

Gonzalo Cabezón Villalba, Ignacio J Amat-Santos, Carlos Dueñas, Diego Lopez Otero, Pablo Catala, Alvaro Aparisi, Javier López-Pais, Carla Eugenia Cacho Antonio, Jordi Candela, Pablo Antúnez Muiños and 14 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Cardiology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Effects of atrial fibrillation on outcomes of influenza hospitalization.International journal of cardiology. Heart & vasculature · 2022
    Article
  8. Review
  9. Article
  10. Usefulness of CJournal of clinical medicine · 2022
    Article
  11. Review
  12. Observational
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Gonzalo Cabezón VillalbaDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.ORCID 0000-0002-6945-1446
Ignacio J Amat-SantosDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Carlos DueñasHospital Clínico Universitario de Valladolid, Valladolid, Spain.
Diego Lopez OteroComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Pablo CatalaDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Alvaro AparisiDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Javier López-PaisComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Carla Eugenia Cacho AntonioComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Jordi CandelaDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Pablo Antúnez MuiñosComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Jose Francisco GilDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Teba Gonzalez FerreroComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Marta MarcosDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Marta Pérez-PozaComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Gino RojasDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Oscar Otero GarciaComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Carlos VerasDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Victor Jiménez RamosComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
Aitor UribarriDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Ana RevillaDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Pablo Elpidio Garcia-GranjaDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Itziar GómezDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
José Ramón González-JuanateyComplejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
J Alberto San RománDepartment of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain. asanroman@secardiologia.es.ORCID 0000-0003-0764-0839
Hospital Clínico Universitario de Valladolid · ESComplejo Hospitalario Universitario de Santiago · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular risk factors and usage of cardiovascular medication are prevalent among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular implications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease (HD) and taking cardiovascular medications in a population diagnosed of COVID-19 who required hospitalization. Also, we studied the development of cardiovascular events during hospitalization.

methodsConsecutive patients with definitive diagnosis of COVID-19 made by a positive real time- -polymerase chain reaction of nasopharyngeal swabs who were admitted to the hospital from March 15 to April 14 were included in a retrospective registry. The association of HD with mortality and with mortality or respiratory failure were the primary and secondary objectives, respectively.

resultsA total of 859 patients were included in the present analysis. Cardiovascular risk factors were related to death, particularly diabetes mellitus (hazard ratio in the multivariate analysis: 1.810 [1.159- -2.827], p = 0.009). A total of 113 (13.1%) patients had HD. The presence of HD identified a group of patients with higher mortality (35.4% vs. 18.2%, p < 0.001) but HD was not independently related to prognosis; renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, diuretics and beta-blockers did not worsen prognosis. Statins were independently associated with decreased mortality (0.551 [0.329-0.921], p = 0.023). Cardiovascular events during hospitalization identified a group of patients with poor outcome (mortality 31.8% vs. 19.3% without cardiovascular events, p = 0.007).

conclusionsThe presence of HD is related to higher mortality. Cardiovascular medications taken before admission are not harmful, statins being protective. The development of cardiovascular events during the course of the disease is related to poor outcome.

Indexed as

PandemicsAgedCardiovascular AgentsComorbidityCOVID-19FemaleHeart DiseasesHumansMalePrognosisRetrospective StudiesSARS-CoV-2Cardiovascular Agentscardiovascular diseasesCOVID-19diabetes mellitusheart failurestatins

Identifiers

PMID33843043
PMCPMC8169179
OpenAlexW3137206914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.